GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoZenge AB (FRA:8LY) » Definitions » Inventories, Raw Materials & Components

OncoZenge AB (FRA:8LY) Inventories, Raw Materials & Components : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is OncoZenge AB Inventories, Raw Materials & Components?

OncoZenge AB's inventories, raw materials & components for the quarter that ended in Dec. 2024 was €0.00 Mil.


OncoZenge AB Inventories, Raw Materials & Components Historical Data

The historical data trend for OncoZenge AB's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoZenge AB Inventories, Raw Materials & Components Chart

OncoZenge AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Inventories, Raw Materials & Components
- - - - -

OncoZenge AB Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

OncoZenge AB Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


OncoZenge AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoZenge AB (FRA:8LY) » Definitions » Inventories, Raw Materials & Components
Traded in Other Exchanges
Address
Gustavslundsvagen 34, Bromma, SWE, 167 51
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.

OncoZenge AB Headlines

No Headlines